American Society of Hirudotherapy

Stopped flow fluorescence energy transfer measurement of the rate constants describing the reversible formation and the irreversible rearrangement of the elastase-alpha1-proteinase inhibitor complex

Research article published in The Journal of biological chemistry (1998)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: In vitro / laboratoryDrug DevelopmentMellet P · The Journal of biological chemistry, 1998

Abstract

Serpins are thought to inhibit proteinases by first forming a Michaelis-type complex that later converts into a stable inhibitory species. However, there is only circumstantial evidence for such a two-step reaction pathway. Here we directly observe the sequential appearance of two complexes by measuring the time-dependent change in fluorescence resonance energy transfer between fluorescein-elastase and rhodamine-alpha1-protease inhibitor. A moderately tight initial Michaelis-type complex EI1 (Ki = 0.38-0.52 microM) forms and dissociates rapidly (k1 = 1.5 x 10(6) M-1 s-1, k-1 = 0.58 s-1). EI1 then slowly converts into EI2 (k2 = 0.13 s-1), the fluorescence intensity of which is stable for at least 50 s. The two species differ by their donor-acceptor energy transfer efficiency (0. 41 and 0.26, respectively). EI2 might be the final product of the elastase + inhibitor association because its transfer efficiency is the same as that of a complex incubated for 30 min. The time-dependent change in fluorescence resonance energy transfer between fluorescein-elastase and rhodamine-eglin c, a canonical inhibitor, again allows the fast formation of a complex to be observed. However, this complex does not undergo any fluorescently detectable transformation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsEnergy TransferFluorescein-5-isothiocyanateFluorescent DyesKineticsLeukocyte ElastaseModels, ChemicalPancreasProteinsRecombinant ProteinsSerpinsSpectrometry, FluorescenceSwineTime Factorsalpha 1-Antitrypsin

Summary

Using fluorescence resonance energy transfer, the authors observed sequential formation of a Michaelis complex (Ki 0.38-0.52 microM) and a stable complex during elastase inhibition by alpha1-proteinase inhibitor; eglin c formed only a fast initial complex with no further rearrangement.

Context

The abstract used fluorescence resonance energy transfer to directly observe the sequential two-step inhibition mechanism of elastase by alpha1-proteinase inhibitor, measuring rapid formation of an initial Michaelis-type complex (Ki = 0.38–0.52 µM) followed by slower rearrangement into a stable inhibitory species. The study also examined elastase interaction with eglin c, described in the abstract as a 'canonical inhibitor,' which formed an initial complex without undergoing any fluorescently detectable transformation. The abstract provides no information about leeches, hirudotherapy, or the biological origin of eglin c. There is no leech link from this abstract.

Citation

Reference (Vancouver style)

Mellet P, Boudier C, Mely Y, Bieth JG. Stopped flow fluorescence energy transfer measurement of the rate constants describing the reversible formation and the irreversible rearrangement of the elastase-alpha1-proteinase inhibitor complex. J Biol Chem. 1998;273(15):9119-9123. doi:10.1074/jbc.273.15.9119. PMID: 9535901

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.